Supplementary Materials for

Bioactive Steroids from the Red Sea Soft Coral *Sinularia polydactyla*

Mohamed A. Tammam ^{1,2}, Lucie Rárová ^{3,*}, Marie Kvasnicová ³, Gabriel Gonzalez ³, Ahmed M. Emam ², Aldoushy Mahdy ⁴, Miroslav Strnad ³, Efstathia Ioannou ¹ and Vassilios Roussis ^{1,*}

- ¹ Section of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece; mtammam@pharm.uoa.gr (M.A.T.); eioannou@pharm.uoa.gr (E.I.)
- ² Department of Biochemistry, Faculty of Agriculture, Fayoum University, 63514 Fayoum, Egypt; ame01@fayoum.edu.eg (A.M.E.)
- ³ Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, and Faculty of Science, Palacký University, Šlechtitelů 27, Olomouc CZ-78371, Czech Republic; kvasnicova@ueb.cas.cz (M.K.); gonzalez.gabriel@seznam.cz (G.G.); miroslav.strnad@upol.cz (M.S.)
- ⁴ Department of Zoology, Faculty of Science, Al-Azhar University (Assiut Branch), 71524 Assiut, Egypt; aldoushy@azhar.edu.eg (A.M.)
- * Correspondence: lucie.rarova@upol.cz (L.R.); roussis@pharm.uoa.gr (V.R.); Tel.: +420-5856-34850698 (L.R.); +30-210-727-4592 (V.R.)

Table of Contents

Figure S1. Compounds 3–7, 9–12, 14–20 and 22–26 did not affect the relative amount of E-selectin on the	
cell surface of endothelial cells that were pretreated with 10 μ M compounds for 30 min and	
subsequently stimulated with 10 ng/ml 1NF α for 4 h. Data are means ± SDs (<i>n</i> = 3).	53
Figure S2. ¹ H NMR spectrum of (9 <i>E</i> ,22 <i>E</i> ,24 <i>R</i>)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),22-	
dien-8-one (1) in CDCl3.	54
Figure S3. HSQC spectrum of $(9E,22E,24R)$ -3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),22-	
dien-8-one (1) in CDCl ₃ .	S4
Figure S4. HMBC spectrum of (9 <i>E</i> ,22 <i>E</i> ,24 <i>R</i>)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),22-	
dien-8-one (1) in CDCl ₃ .	S5
Figure S5. COSY spectrum of (9 <i>E</i> ,22 <i>E</i> ,24 <i>R</i>)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),22-	
dien-8-one (1) in CDCl ₃ .	S5
Figure S6. HR-APCIMS spectrum of $(9E,22E,24R)$ -3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-	
9(11),22-dien-8-one (1).	S6
Figure S7 . ¹ H NMR spectrum of (9 <i>E</i>)-3β-hydroxy-4α,24-dimethyl-8,9-seco-5α-cholesta-9(11),24(28)-dien-	
8-one (2) in CDCl ₃ .	S6
Figure S8 . COSY spectrum of (9 <i>E</i>)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),24(28)-dien-8-	
one (2) in CDCl ₃ .	S7
Figure S9 . HR-APCIMS spectrum of (9 <i>E</i>)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),24(28)-	
dien-8-one (2).	S7
Figure S10. ¹ H NMR spectrum of (22 <i>E</i> ,24 <i>R</i>)-4 α ,24-dimethyl-5 α -cholest-22-en-3 β ,8 β -diol (6) in CDCl ₃ .	S8
Figure S11 . HSOC spectrum of $(22E, 24R) - 4\alpha, 24$ -dimethyl- 5α -cholest-22-en- $3\beta, 8\beta$ -diol (6) in CDCl ₃ .	58
Figure S12 HMBC spectrum of $(22F 24R)$ -4 α 24-dimethyl-5 α -cholest-22-en-3 β 8 β -diol (6) in CDCl ₃	59
Figure S13 COSY spectrum of $(22F, 24R) - 4\alpha/24$ -dimethyl-5\alpha-cholest-22-en-3\beta 8\beta-diol (6) in CDCl ₃	59
Figure S14 HR-APCIMS spectrum of $(22F, 24R)$ -4 α 24-dimethyl-5 α -cholest-22-en-38 88-diol (6)	S10
Figure S15 ¹ H NMR spectrum of (23F)-22a 28-epidiovy- $4a$ 24-dimethyl- $5a$ -cholest-23-ep-38 88-diol (8)	510
in CDCl ₂	S 10
Figure S16 HSOC spectrum of (23E)-22x 28-apidiovy Ax 24-dimethyl-5x-cholect-23-ap.3k 8k-diol (8) in	510
CDCl	S 11
Figure \$17 HMBC spectrum of (23E) 22 a 28 anidioxy 4 a 24 dimethyl 5 a cholest 23 on 36 8 b diel (8) in	511
$CDCl_{2}$	S 11
Figure S18 COSV spectrum of (23E)-22x 28-epidioxy-1x 24-dimethyl-5x-cholest-23-ep-38 88-diol (8) in	511
$CDCl_{a}$	C10
Eigura S10 HP ADCIMS spectrum of (22E) 22x 28 apidiovy 4x 24 dimethyl 5x abolast 22 ap 28 88 dial	512
Figure 517. The AT Chivid Spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of the spectrum of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of $(25L)$ -22 a , 26-epidioxy-4 a , 24-dimension-site of $(25L)$ -22 a , 26-epidioxy-4 a , 26-epidioxy-4 a , 26-epidioxy-4 a , 28-epidioxy-4 a , 28	C10
(0). Eigener S20 111 NIME an external of $(22E)$ 22 a 28 articlicum 4 a 24 dimethal Eq. ab about 22 an 20 80 110 trial	512
Figure S20. The NMR spectrum of $(23L)$ -22 α , 28-epidioxy-4 α , 24-dimethyl-5 α -cholest-25-eh-5p, 8p, 11p-triol	C12
(13) In CDCB. C $(22T) 22 = 22 = 22 = 22 = 22 = 22 = 22 = $	513
Figure S21. HSQC spectrum of $(23E)$ -22 α , 28-epidioxy-4 α , 24-dimetry 1-5 α -choiest-25-en-5 β , 8 β , 11 β -triol	610
(13) In CDCI3. 1 (220 H) (220 $\text{H})$ (220 H	513
Figure S22. HMBC spectrum of $(23E)$ -22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -triol	014
(13) In CDCl ₃ .	S14
Figure S23. COSY spectrum of $(23E)$ -22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -triol	
(13) in CDCl ₃ .	S14
Figure S24. HR-APCIMS spectrum of (23 <i>E</i>)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -	
triol (13).	S15
Figure S25 . ¹ H NMR spectrum of (22 <i>E</i>)-24-methyl-cholesta-5,22,24(28)-trien-3 <i>β</i> ,19-diol (20) in CDCl ₃ .	S15
Figure S26 . HSQC spectrum of (22 <i>E</i>)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20) in CDCl ₃ .	S16
Figure S27. HMBC spectrum of (22 <i>E</i>)-24-methyl-cholesta-5,22,24(28)-trien- 3β ,19-diol (20) in CDCl ₃ .	S16
Figure S28. COSY spectrum of (22 <i>E</i>)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20) in CDCl ₃ .	S17
Figure S29. HR-ESIMS spectrum of (22 <i>E</i>)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20).	S17



Figure S1. Compounds 3–7, 9–12, 14–20 and 22–26 did not affect the relative amount of E-selectin on the cell surface of endothelial cells that were pretreated with 10 μ M compounds for 30 min and subsequently stimulated with 10 ng/ml TNF α for 4 h. Data are means ± SDs (*n* = 3).



Figure S2. ¹H NMR spectrum of (9E,22E,24R)- 3β -hydroxy- 4α ,24-dimethyl-8,9-seco- 5α -cholesta-9(11),22-dien-8-one (**1**) in CDCl₃.



Figure S3. HSQC spectrum of (9E,22E,24R)- 3β -hydroxy- 4α ,24-dimethyl-8,9-seco- 5α -cholesta-9(11),22-dien-8-one (**1**) in CDCl₃.



Figure S4. HMBC spectrum of (9E, 22E, 24R)- 3β -hydroxy- 4α , 24-dimethyl-8, 9-seco- 5α -cholesta-9(11), 22-dien-8-one (**1**) in CDCl₃.



Figure S5. COSY spectrum of (9E, 22E, 24R)- 3β -hydroxy- 4α , 24-dimethyl-8, 9-seco- 5α -cholesta-9(11), 22-dien-8-one (**1**) in CDCl₃.



Figure S6. HR-APCIMS spectrum of (9E,22E,24R)- 3β -hydroxy- 4α ,24-dimethyl-8,9-seco- 5α -cholesta-9(11),22-dien-8-one (1).



Figure S7. ¹H NMR spectrum of (9*E*)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),24(28)-dien-8-one (**2**) in CDCl₃.



Figure S8. COSY spectrum of (9*E*)-3β-hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),24(28)-dien-8-one (**2**) in CDCl₃.



Figure S9. HR-APCIMS spectrum of (9*E*)-3 β -hydroxy-4 α ,24-dimethyl-8,9-seco-5 α -cholesta-9(11),24(28)-dien-8-one (**2**).



Figure S10. ¹H NMR spectrum of (22E, 24R)-4 α , 24-dimethyl-5 α -cholest-22-en-3 β , 8 β -diol (6) in CDCl₃.



Figure S11. HSQC spectrum of (22E, 24R)- 4α , 24-dimethyl- 5α -cholest-22-en- 3β , 8β -diol (6) in CDCl₃.



Figure S12. HMBC spectrum of $(22E, 24R)-4\alpha$, 24-dimethyl-5 α -cholest-22-en-3 β , 8 β -diol (6) in CDCl₃.



Figure S13. COSY spectrum of $(22E, 24R)-4\alpha$, 24-dimethyl- 5α -cholest-22-en- 3β , 8β -diol (6) in CDCl₃.



Figure S14. HR-APCIMS spectrum of $(22E, 24R)-4\alpha, 24$ -dimethyl- 5α -cholest-22-en- $3\beta, 8\beta$ -diol (6).



Figure S15. ¹H NMR spectrum of (23*E*)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β -diol (8) in CDCl₃.



Figure S16. HSQC spectrum of (23*E*)-22*α*,28-epidioxy-4*α*,24-dimethyl-5*α*-cholest-23-en-3*β*,8*β*-diol (8) in CDCl₃.



Figure S17. HMBC spectrum of (23*E*)-22*α*,28-epidioxy-4*α*,24-dimethyl-5*α*-cholest-23-en-3*β*,8*β*-diol (8) in CDCl₃.



Figure S18. COSY spectrum of (23E)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β -diol (8) in CDCl₃.



Figure S19. HR-APCIMS spectrum of (23E)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β -diol (8).



Figure S20. ¹H NMR spectrum of (23*E*)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -triol (**13**) in CDCl₃.



Figure S21. HSQC spectrum of (23E)- 22α ,28-epidioxy- 4α ,24-dimethyl- 5α -cholest-23-en- 3β , 8β ,11 β -triol (13) in CDCl₃.



Figure S22. HMBC spectrum of (23E)- 22α ,28-epidioxy- 4α ,24-dimethyl- 5α -cholest-23-en- 3β ,8 β ,11 β -triol (**13**) in CDCl₃.



Figure S23. COSY spectrum of (23*E*)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -triol (13) in CDCl₃.



Figure S24. HR-APCIMS spectrum of (23E)-22 α ,28-epidioxy-4 α ,24-dimethyl-5 α -cholest-23-en-3 β ,8 β ,11 β -triol (**13**).



Figure S25. ¹H NMR spectrum of (22*E*)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20) in CDCl₃.



Figure S26. HSQC spectrum of (22*E*)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20) in CDCl₃.



Figure S27. HMBC spectrum of (22*E*)-24-methyl-cholesta-5,22,24(28)-trien-3*β*,19-diol (**20**) in CDCl₃.



Figure S28. COSY spectrum of (22*E*)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20) in CDCl₃.



Figure S29. HR-ESIMS spectrum of (22*E*)-24-methyl-cholesta-5,22,24(28)-trien-3β,19-diol (20).